person · Reporting owner
RA Capital Nexus Fund III, L.P.
Disclosed activity across 10 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | September 10, 2026 | September 14, 2026 |
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director | June 09, 2026 | June 10, 2026 |
| Climb Bio, Inc.CLYM · Entity 5064 | Director | September 28, 2026 | October 01, 2026 |
| Evommune, Inc.EVMN · Entity 5539 | Director | February 17, 2026 | February 18, 2026 |
| Freenome, Inc.FRNM · Entity 4644 | Director | July 20, 2026 | July 22, 2026 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | March 27, 2026 | March 31, 2026 |
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director | July 20, 2026 | July 22, 2026 |
| Septerna, Inc.SEPN · Entity 2452 | Director | August 12, 2026 | August 14, 2026 |
| Sionna Therapeutics, Inc.SION · Entity 5996 | Director | September 17, 2026 | September 21, 2026 |
| SpyGlass Pharma, Inc.SGP · Entity 5034 | Director | February 09, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date September 10, 2026 · Filed September 14, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2036-09-09 | IndirectSee Footnotes | 16,250 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 16,250 · Balance 16,250 F1: Represents the grant of a stock option to Laura Stoppel in connection with her service on the Issuer's board of directors. The shares subject to the option will vest on the earlier of September 10, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein. F3: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of a stock option to Laura Stoppel in connection with her service on the Issuer's board of directors. The shares subject to the option will vest on the earlier of September 10, 2027 or the date of the Issuer's 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein.
F3: Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Bicara Therapeutics Inc.
Report date June 09, 2026 · Filed June 10, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2036-06-09 | IndirectSee Footnotes | 19,475 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 19,475 · Balance 19,475 F1: Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying this option shall vest upon the earlier of (i) June 9, 2027, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to Dr. Simson's continued service on such vesting date. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying this option shall vest upon the earlier of (i) June 9, 2027, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to Dr. Simson's continued service on such vesting date.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F3: Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Climb Bio, Inc.
Report date September 28, 2026 · Filed October 01, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 10,000 |
Reported balance
After 2026-09-28 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-09-28 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 20,000 |
Reported balance
After 2026-09-28 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-09-28 · Exercise / conversion · Acquired 10,000 · Balance 20,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 30,000 |
Reported balance
After 2026-09-28 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-09-28 · Exercise / conversion · Acquired 10,000 · Balance 30,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 70,000 |
Reported balance
After 2026-09-28 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-09-28 · Exercise / conversion · Acquired 40,000 · Balance 70,000 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,837,101 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,837,101 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: These securities are held directly by Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,226,497 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,226,497 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4: These securities are held directly by the Nexus Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 483,679 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 483,679 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F5: These securities are held directly by the Nexus Fund II. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,671,766 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 3,671,766 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F6: These securities are held directly by Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 841,087 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 841,087 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F7: These securities are held directly by the Account. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 · Expires 2026-09-29 | IndirectSee footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-28 · Exercise / conversion · Disposed 10,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2026-09-29 | IndirectSee Footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-28 · Exercise / conversion · Disposed 10,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2026-09-29 | IndirectSee Footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-28 · Exercise / conversion · Disposed 10,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2026-09-29 | IndirectSee Footnotes | 0 |
Reported balance
After 2026-09-28 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-28 · Exercise / conversion · Disposed 40,000 · Balance 0 F8: Immediately exercisable. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F2: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
F3: These securities are held directly by Fund.
F4: These securities are held directly by the Nexus Fund.
F5: These securities are held directly by the Nexus Fund II.
F6: These securities are held directly by Nexus Fund III.
F7: These securities are held directly by the Account.
F8: Immediately exercisable.
Evommune, Inc.
Report date February 17, 2026 · Filed February 18, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 2,710,293 |
Reported balance
After 2026-02-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 35,868 · Balance 2,710,293 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 784,345 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 784,345 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F2: Held directly by the Fund.
F3: Held directly by the Nexus Fund III.
Freenome, Inc.
Report date July 20, 2026 · Filed July 22, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 7,311,711 |
Reported balance
After 2026-07-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-07-20 · Grant · Acquired 6,561,711 · Balance 7,311,711 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F2: Received in the Business Combination in exchange for 4,886,446 shares of Series B Preferred Stock, 4,111,335 shares of Series C Preferred Stock, 4,093,925 shares of Series D Preferred Stock and 10,103,180 shares of Series F Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 970,950 |
Reported balance
After 2026-07-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-07-20 · Grant · Acquired 970,950 · Balance 970,950 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F5: Received in the Business Combination in exchange for 1,920,093 shares of Series B Preferred Stock and 1,512,104 shares of Series C Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F6: Held directly by the Nexus Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 553,703 |
Reported balance
After 2026-07-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-07-20 · Grant · Acquired 553,703 · Balance 553,703 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F7: Received in the Business Combination in exchange for 1,754,539 shares of Series D Preferred Stock and 202,739 shares of Series F Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F8: Held directly by Nexus Fund II. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 908,103 |
Reported balance
After 2026-07-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-07-20 · Grant · Acquired 908,103 · Balance 908,103 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F9: Received in the Business Combination in exchange for 3,210,040 shares of Series F Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F10: Held directly by Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 367,427 |
Reported balance
After 2026-07-20 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-07-20 · Grant · Acquired 367,427 · Balance 367,427 F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination"). F11: Received in the Business Combination in exchange for 873,834 shares of Series B Preferred Stock and 424,978 shares of Series C Preferred Stock of Old Freenome. F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F12: Held directly by the Account. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 12,230,122 |
Reported balance
After 2026-07-20 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2026-07-20 · Grant · Acquired 4,918,411 · Balance 12,230,122 F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F4: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,245,068 |
Reported balance
After 2026-07-20 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2026-07-20 · Grant · Acquired 336,965 · Balance 1,245,068 F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F10: Held directly by Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: Received on July 20, 2026 pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer, StarNet Merger Sub II, LLC, a wholly-owned subsidiary of the Issuer, and Freenome Holdings, Inc. ("Old Freenome") (the "Business Combination").
F2: Received in the Business Combination in exchange for 4,886,446 shares of Series B Preferred Stock, 4,111,335 shares of Series C Preferred Stock, 4,093,925 shares of Series D Preferred Stock and 10,103,180 shares of Series F Preferred Stock of Old Freenome.
F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F4: Held directly by the Fund.
F5: Received in the Business Combination in exchange for 1,920,093 shares of Series B Preferred Stock and 1,512,104 shares of Series C Preferred Stock of Old Freenome.
F6: Held directly by the Nexus Fund.
F7: Received in the Business Combination in exchange for 1,754,539 shares of Series D Preferred Stock and 202,739 shares of Series F Preferred Stock of Old Freenome.
F8: Held directly by Nexus Fund II.
F9: Received in the Business Combination in exchange for 3,210,040 shares of Series F Preferred Stock of Old Freenome.
F10: Held directly by Nexus Fund III.
F11: Received in the Business Combination in exchange for 873,834 shares of Series B Preferred Stock and 424,978 shares of Series C Preferred Stock of Old Freenome.
F12: Held directly by the Account.
Mineralys Therapeutics, Inc.
Report date March 27, 2026 · Filed March 31, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 5,767,221 |
Reported balance
After 2026-03-27 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-03-27 · Purchase · Acquired 310,700 · Balance 5,767,221 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.31 to $24.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 5,825,521 |
Reported balance
After 2026-03-30 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-03-30 · Purchase · Acquired 58,300 · Balance 5,825,521 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,867,229 |
Reported balance
Holding disclosure · report date 2026-03-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,867,229 F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5: Held directly by Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.31 to $24.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").
F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5: Held directly by Nexus Fund III.
Parabilis Medicines, Inc.
Report date July 20, 2026 · Filed July 22, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,383,526 |
Reported balance
After 2026-07-20 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-07-20 · Purchase · Acquired 98,433 · Balance 26,383,526 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.53 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,416,513 |
Reported balance
After 2026-07-20 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-07-20 · Purchase · Acquired 32,987 · Balance 26,416,513 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.55 to $27.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,438,209 |
Reported balance
After 2026-07-21 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-07-21 · Purchase · Acquired 21,696 · Balance 26,438,209 F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.46 to $28.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,444,713 |
Reported balance
After 2026-07-21 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-07-21 · Purchase · Acquired 6,504 · Balance 26,444,713 F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.83 to $29.79 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,482,436 |
Reported balance
After 2026-07-21 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-07-21 · Purchase · Acquired 37,723 · Balance 26,482,436 F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.97 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 26,529,686 |
Reported balance
After 2026-07-22 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-07-22 · Purchase · Acquired 47,250 · Balance 26,529,686 F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.35 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Fund. |
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,648,278 |
Reported balance
Holding disclosure · report date 2026-07-20 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,648,278 F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F9: Held directly by Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.53 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F3: Held directly by the Fund.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.55 to $27.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.46 to $28.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.83 to $29.79 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.97 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $29.35 to $30.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F9: Held directly by Nexus Fund III.
Septerna, Inc.
Report date August 12, 2026 · Filed August 14, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 4,777,415 |
Reported balance
After 2026-08-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 746,500 · Balance 4,777,415 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 725,443 |
Reported balance
After 2026-08-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-08-12 · Sale · Disposed 746,500 · Balance 725,443 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3: Held directly by the Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
F2: Held directly by the Fund.
F3: Held directly by the Nexus Fund III.
Sionna Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,482,612 |
Reported balance
After 2026-09-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-09-17 · Sale · Disposed 3,415,011 · Balance 3,482,612 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 3,448,812 |
Reported balance
After 2026-09-17 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-09-17 · Sale · Disposed 33,800 · Balance 3,448,812 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F2: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 650,307 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 650,307 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,198,082 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,198,082 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5: Held directly by the Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 159,033 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 159,033 F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6: Held directly by the Account. |
Filing footnotes · ownership attribution and instrument terms
F1: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2: Held directly by the Fund.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Held directly by the Nexus Fund.
F5: Held directly by the Nexus Fund III.
F6: Held directly by the Account.
SpyGlass Pharma, Inc.
Report date February 09, 2026 · Filed February 11, 2026
Jointly reported with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,524,473 |
Reported balance
After 2026-02-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-09 · Conversion · Acquired 2,524,473 · Balance 2,524,473 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,806,644 |
Reported balance
After 2026-02-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-02-09 · Conversion · Acquired 1,806,644 · Balance 1,806,644 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 5,966,439 |
Reported balance
After 2026-02-09 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-02-09 · Purchase · Acquired 3,441,966 · Balance 5,966,439 F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 2,054,678 |
Reported balance
After 2026-02-09 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-02-09 · Purchase · Acquired 248,034 · Balance 2,054,678 F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-09 · Conversion · Disposed 1,150,941 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-09 · Conversion · Disposed 767,294 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Series C-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-09 · Conversion · Disposed 1,150,941 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Series C-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-09 · Conversion · Disposed 767,294 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-09 · Conversion · Disposed 222,591 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3: Held directly by the Fund. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-02-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-09 · Conversion · Disposed 272,056 · Balance 0 F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4: Held directly by the Nexus Fund III. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3: Held directly by the Fund.
F4: Held directly by the Nexus Fund III.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 12 | $40.61 | $487.32 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 22 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 662,254 F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 2 | $40.61 | $81.22 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 21 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,899,079 F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 14,325 | $40.01 | $573,143.25 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 20 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 168,202 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 12,126 | $40.01 | $485,161.26 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 19 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,205,843 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 18,684 | $40.01 | $747,546.84 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 18 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 662,266 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 2,276 | $40.01 | $91,062.76 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 17 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,899,081 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.59 to $40.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 2,092 | $39.57 | $82,780.44 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 16 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 182,527 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 1,770 | $39.57 | $70,038.90 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 15 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,217,969 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 2,728 | $39.57 | $107,946.96 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 14 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 680,950 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 332 | $39.57 | $13,137.24 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 13 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,901,357 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.40 to $40.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 331 | $42.10 | $13,935.10 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 12 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 184,619 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.13 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 280 | $42.10 | $11,788.00 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 11 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,219,739 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.13 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 433 | $42.10 | $18,229.30 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 10 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 683,678 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.13 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 53 | $42.10 | $2,231.30 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 9 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,901,689 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.13 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 10,707 | $41.05 | $439,522.35 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 8 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 184,950 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 9,063 | $41.05 | $372,036.15 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 7 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,220,019 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 13,964 | $41.05 | $573,222.20 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 6 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 684,111 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 1,701 | $41.05 | $69,826.05 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,901,742 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 13,734 | $40.20 | $552,106.80 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 195,657 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 11,626 | $40.20 | $467,365.20 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,229,082 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Nexus Fund III. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 17,913 | $40.20 | $720,102.60 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 698,075 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 01:43 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 2,182 | $40.20 | $87,716.40 |
DisclosureSEC source: 0001231919-25-000527 · form4-11202025_011134.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,903,443 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.85 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 10,476 | $39.58 | $414,640.08 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 8 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 209,391 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.81 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Account. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 17,118 | $39.58 | $677,530.44 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 7 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,240,708 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.81 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by Nexus Fund III. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 31,392 | $39.58 | $1,242,495.36 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 6 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 715,988 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.81 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 3,624 | $39.58 | $143,437.92 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,905,625 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.81 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 24, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 107,941 | $39.50 | $4,263,669.50 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 219,867 F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by the Account. Read SEC document |
| October 24, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 66,672 | $39.50 | $2,633,544.00 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,257,826 F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by Nexus Fund III. Read SEC document |
| October 24, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 122,271 | $39.50 | $4,829,704.50 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 747,380 F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| October 24, 2025 Filed Oct 29, 2025 01:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 14,116 | $39.50 | $557,582.00 |
DisclosureSEC source: 0001231919-25-000364 · form4-10292025_011037.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,909,249 F1 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 1,176,470 | $25.50 | $29,999,985.00 |
DisclosureSEC source: 0001415889-25-023893 · form4-09082025_090941.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 5,456,521 F1 · ownership.nature: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 20:51 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001415889-25-018284 · form4-06262025_080614.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2035-06-23 F1 · derivative.exercise_date: Represents the grant of a stock option to Laura Stoppel pursuant to the Issuer's non-employee director compensation policy. The shares subject to the option will vest on the earlier of June 24, 2026 or the date of the Issuer's 2026 annual stockholder meeting, subject to Dr. Stoppel's continuous service as a director through such vesting date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein. F3 · ownership.nature: Laura Stoppel is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 22:46 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 16,623 | $0.00 Strike: $10.24 | $0.00 |
DisclosureSEC source: 0001415889-25-017903 · form4-06202025_100616.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 16,623 Underlying: Common Stock · 16,623 shares Expires 2035-06-16 F1 · derivative.exercise_date: Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares subject to the option shall vest on the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to Dr. Simson's continued service to the Issuer through such vesting date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Jake Simson is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:15 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,959 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001415889-25-017421 · form4-06162025_090600.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 19,959 Underlying: Common Stock · 19,959 shares Expires 2035-06-11 F1 · derivative.exercise_date: This option was granted to Joshua Resnick pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest in full upon the earlier of June 12, 2026 or the date of the Issuer's next annual meeting, subject to Dr. Resnick's continued service as a director through such date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein. F3 · ownership.nature: Under Dr. Resnick's arrangement with the Adviser, Dr. Resnick holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III, and the Account. Dr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:34 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 23,746 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0001415889-25-016483 · form4-06102025_080624.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 23,746 Underlying: Common Stock · 23,746 shares Expires 2035-06-09 F1 · derivative.exercise_date: Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026, and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to Dr. Simson's continued service on such vesting date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III. Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:21 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001415889-25-015766 · form4-06052025_080655.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's continuous service through such date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"),and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Dr. Andrew Levin is a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors. Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 23:56 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 1,296,296 | $13.50 | $17,499,996.00 |
DisclosureSEC source: 0001415889-25-008257 · form4-03172025_110349.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,280,051 F1 · ownership.nature: Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund"). F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| February 13, 2025 Filed Feb 25, 2025 02:41 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option (Right to Buy) · Derivative | 32,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001415889-25-005380 · form4-02252025_020233.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director RA Capital Healthcare Fund LP · CIK 0001315082 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director Shah Rajeev M. · CIK 0001619841 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 32,900 Underlying: Common Stock · 32,900 shares Expires 2035-02-13 F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F3 · ownership.nature: Derek DiRocco is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of the Fund and the Nexus Fund III. Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries C Preferred Stock · Derivative | 1,091,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 16 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 746,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by Nexus Fund III. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries C Preferred Stock · Derivative | 4,364,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 15 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,987,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries B Preferred Stock · Derivative | 2,155,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 14 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,475,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by Nexus Fund III. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries B Preferred Stock · Derivative | 923,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 13 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 632,244 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries A Preferred Stock · Derivative | 124,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 12 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 85,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries A Preferred Stock · Derivative | 451,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 11 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 309,069 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries A Preferred Stock · Derivative | 1,229,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 10 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 841,716 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries Seed Preferred Stock · Derivative | 138,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 9 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 94,486 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F6 · ownership.nature: Held directly by the Account. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries Seed Preferred Stock · Derivative | 319,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 8 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 218,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: Held directly by the Nexus Fund. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries Seed Preferred Stock · Derivative | 819,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · derivative · entry 7 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 560,642 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | PurchaseCommon Stock | 102,414 | $18.00 | $1,843,452.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · nonDerivative · entry 6 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,324,498 F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: Held directly by Nexus Fund III. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:04 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | PurchaseCommon Stock | 1,022,586 | $18.00 | $18,406,548.00 |
DisclosureSEC source: 0001415889-25-003504 · form4-02102025_100210.xml · nonDerivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 6,923,365 F2 · ownership.nature: Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, he Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.